Literature DB >> 22684771

Identification of protease inhibitors by a fast fluorimetric assay.

Nunzianna Doti1, Domenico Raimondo, Marco Sabatella, Menotti Ruvo.   

Abstract

Anomalous protease activities are associated with many diseases. Great efforts are paid for selecting specific protease modulators for therapeutic approaches. We have selected new modulators of enzyme activity by an homogeneous assay based on a doubly labeled small peptide used as substrate of trypsin. The substrate incorporates the fluorophore 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS) at one end and an EDANS-quenching moiety (Dabcyl, (4-(4-dimethylaminophenylazo)-benzoic acid)) on the other end. Following cleavage by trypsin, the peptide-EDANS product is released interrupting the fluorescence resonance energy transfer effect and yielding bright fluorescence, which can be detected using excitation wavelengths at 335-345 nm and emission wavelengths at 485-510 nm. The method optimized, tested by detecting the strong inhibiting effect of α1-antitrypsin on trypsin activity, has been developed on 384 multi-well plates in a volume of 10 μL, using an automated platform. From the screening of a chemical library, four compounds that inhibit trypsin activity with IC50s in the micromolar range have been identified. Interestingly, the most active compound (M4) shows a chemical structure recapitulating that of other more potent inhibitors with thiourea and halogenated centers. Molecular docking studies show that M4 is a competitive inhibitor recognizing most residues within or nearby the catalytic pocket.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22684771     DOI: 10.1007/s12033-012-9566-z

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  19 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Structural and mechanistic insight into how antibodies inhibit serine proteases.

Authors:  Rajkumar Ganesan; Charles Eigenbrot; Daniel Kirchhofer
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

Review 3.  Serine proteases of the human immune system in health and disease.

Authors:  Kirstin M Heutinck; Ineke J M ten Berge; C Erik Hack; Jörg Hamann; Ajda T Rowshani
Journal:  Mol Immunol       Date:  2010-05-26       Impact factor: 4.407

Review 4.  Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection.

Authors:  Weibo Luo; Yingfei Wang; Georg Reiser
Journal:  Brain Res Rev       Date:  2007-08-29

5.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Authors:  Amy D Shapiro; Margaret V Ragni; Leonard A Valentino; Nigel S Key; Neil C Josephson; Jerry S Powell; Gregory Cheng; Arthur R Thompson; Jaya Goyal; Karen L Tubridy; Robert T Peters; Jennifer A Dumont; Donald Euwart; Lian Li; Bengt Hallén; Peter Gozzi; Alan J Bitonti; Haiyan Jiang; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

6.  Synthesis and biochemical evaluation of triazole/tetrazole-containing sulfonamides against thrombin and related serine proteases.

Authors:  Rogelio Siles; Yuko Kawasaki; Patrick Ross; Ernesto Freire
Journal:  Bioorg Med Chem Lett       Date:  2011-07-14       Impact factor: 2.823

7.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

8.  Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors.

Authors:  Alexander Adibekian; Brent R Martin; Chu Wang; Ku-Lung Hsu; Daniel A Bachovchin; Sherry Niessen; Heather Hoover; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2011-05-15       Impact factor: 15.040

9.  Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis.

Authors:  Yoshikane Yamauchi; Yotaro Izumi; Masanori Inoue; Hiroaki Sugiura; Taichiro Goto; Masaki Anraku; Takashi Ohtsuka; Mitsutomo Kohno; Kenzo Soejima; Hiroaki Nomori
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

10.  Versatile assays for high throughput screening for activators or inhibitors of intracellular proteases and their cellular regulators.

Authors:  Hideki Hayashi; Michael Cuddy; Vincent Chih-Wen Shu; Kenneth W Yip; Charitha Madiraju; Paul Diaz; Toshifumi Matsuyama; Muneshige Kaibara; Kohtaro Taniyama; Stefan Vasile; Eduard Sergienko; John C Reed
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.